CD274 and pneumonitis: If patients did not meet PACIFIC criteria for durvalumab eligibility, this was mainly caused by disease progression during platinum-based CRT, followed by therapy-related pneumonitis and a PD-L1 expression of 0% as defined by the EMA drug approval terms.